{
    "nctId": "NCT00122356",
    "briefTitle": "Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment",
    "officialTitle": "Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 303,
    "primaryOutcomeMeasure": "Changes in lumbar vertebra and femoral neck bone mineral density (BMD) T-score after 5 years of anastrozole treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal\n* Adequately diagnosed and treated Stage I-IIIa early breast cancer\n* Oestrogen receptor and/or progesterone receptor positive breast cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2\n* Hormone replacement therapy (HRT) must be discontinued at least 2 weeks prior to registration\n* Any prior tamoxifen taken for a total of 8 weeks or less\n* Any prior anastrozole taken for a total of 4 weeks or less\n* Anastrozole is clinically indicated to be the best adjuvant strategy\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Clinical or radiological evidence of distant spread of disease\n* Prior treatment with bisphosphonates within the past 12 months\n* Prior treatment with continuous systemic corticosteroids within the past 12 months\n* Prior use of parathyroid hormone for more than 1 week\n* Prior use of systemic sodium fluoride for \\> 3 months during the past 2 years\n* Currently treated with any drugs known to affect the skeleton\n* Abnormal renal function (serum creatinine greater than or equal to 265.2 mmol/L)\n* History of diseases with influence on bone metabolism. Patients with lactose intolerance are also excluded\n* Delayed oesophageal emptying such as stricture or achalasia\n* Hypersensitivity to alendronate or anastrozole\n* Previous or concomitant malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix\n* AST/SGOT and/or ALT/SGPT \\> 3 x ULN in combination with other laboratory and clinical abnormalities indicating liver insufficiency\n* Fracture due to minimal trauma, demonstrated radiologically",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}